Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Capsule Endoscopy Complements Magnetic Resonance Enterography and Endoscopy in Evaluating Small Bowel Crohn’s Disease
Prichard, David O. , Smyth, Matthew D. , Penner, Carlie , Lakhani, Alam , Sarkhy, Ahmed Al , Enns, Robert , Jamieson, Douglas H., Jacobson, Kevan , Hamilton, Zachary, Savage, Thomas, Carroll, Matthew W. , Lemberg, Daniel A.

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | August 2, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jcag/gwz028 | PMID 33241181 Get It

Abstract Aims Wireless capsule endoscopy (WCE) and magnetic resonance enterography (MRE) are increasingly utilized to evaluate the small bowel (SB) in Crohn’s disease (CD). The primary aims were to compare the ability of WCE and MRE to detect SB inflammation in children with newly diagnosed CD, and in the terminal ileum (TI) to compare them to ileo-colonoscopy. Secondary aims were to compare diagnostic accuracy of WCE and MRE and changes in Paris classification after each study. Methods Patients (10 to 17 years of age) requiring ileo-colonoscopy for suspected CD were invited to participate. Only patients with endoscopic/histologic evidence of CD underwent MRE and WCE. SB inflammation and extent were documented and comparative analyses performed. Results Of 38 initially recruited subjects, 20 completed the study. WCE and MRE were similarly sensitive in identifying active TI inflammation (16 [80%] versus 12 [60%]) and any SB inflammation (17 [85%] versus 16 [80%]). However, WCE detected more extensive SB disease than MRE with active inflammation throughout the SB in 15 [75%] versus 1 [5%] patient (P < 0.001). Moreover, WCE was more likely to detect proximal SB disease (jejunum and ileum) compared to MRE (85% versus 50%, P = 0.04). Overall, the Paris classification changed in 65% and 85% of patients following MRE and WCE, respectively. Conclusions WCE is as sensitive as MRE for identifying active TI inflammation, but appears more sensitive in identifying more proximal SB inflammation. In the absence of concern regarding stricturing or extra-luminal disease WCE can be considered for the evaluation of suspected SB CD.
A Retrospective Case Series of Synovial Sarcoma of the Upper Extremity
Post, Joel M. , Folpe, Andrew L. , Wilke, Benjamin K. , Wilke, B K , Houdek, Matthew T. , Kakar, Sanjeev

Mayo Clinic

Sarcoma | August 1, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-7

10.1155/2019/8704936 | PMID 31467480 Get It

Purpose. Previous studies have grouped the treatment of axial and appendicular synovial sarcomas. The purpose of this study was to assess the prognostic variables of upper extremity synovial sarcomas (UESS) and compare the outcomes of those who underwent a nononcologic or inadvertent excision prior to definitive resection to those who underwent an initial oncologic resection. Methods. We reviewed the records of 23 UESS treated with definitive surgery at our institution between 1990 and 2014. There were 13 women and 10 men with a median age of 30 years (6–60) and median follow-up of 63 months (15–248). Prognostic variables, recurrence-free survival (RFS), and overall survival (OS) were then assessed. Results. Fifteen patients (65%) had a prior unplanned excision. Five patients required an amputation to obtain local control of disease. There were 3 observed local recurrences and 2 distant metastases at a median of 45 months from presentation. We found no difference in need for amputation, RFS, or OS between those who had undergone a planned excision and those who had an unplanned excision. Conclusion. While we were unable to find a significant difference in outcomes or amputation rates between those who underwent reexcision of a previously unplanned excision and those who underwent an initial planned resection, the high rate of unplanned excision is troubling and should remind practitioners to consider sarcoma in the differential of all upper extremity masses.
Effects of Hormone Therapy on Heart Fat and Coronary Artery Calcification Progression: Secondary Analysis From the KEEPS Trial
Khoudary, Samar R. El , Zhao, Qian , Venugopal, Vidya, Black, Dennis M. , Harman, S. Mitchell , Cedars, Marcelle I. , Hopkins, Paul N. , Kearns, Ann E. , Miller, Virginia M. , Taylor, Hugh S. , Budoff, Matthew J. , El Khoudary, Samar R , Budoff, Matthew , Manson, JoAnn E. , Brooks, Maria M. , Santoro, Nanette F.

Mayo Clinic

Journal of the American Heart Association | August 1, 2019 | Volume: 8 | Issue: 15 | Pages: No page available

10.1161/jaha.119.012763 | PMID 31652073 Get It

Background Heart fats (epicardial and paracardial adipose tissue [PAT]) are greater after menopause. Endogenous estrogen may regulate these fat depots. We evaluated the differential effects of hormone therapy formulations on heart fat accumulations and their associations with coronary artery calcification ( CAC ) progression in recently menopausal women from KEEPS (Kronos Early Estrogen Prevention Study). Methods and Results KEEPS was a multicenter, randomized, placebo‐controlled trial of the effects of 0.45 mg/d oral conjugated equine estrogens and 50 µg/d transdermal 17β‐estradiol, compared with placebo, on 48‐month progression of subclinical atherosclerosis among 727 early menopausal women. CAC progression was defined if baseline CAC score was 0 and 48‐month CAC score was >0 or if baseline CAC score was >0 and <100 and annualized change in CAC score was ≥10. Of 727 KEEPS participants, 474 (mean age: 52.7 [SD: 2.6]; 78.1% white) had computed tomography–based heart fat and CAC measures at both baseline and 48 months. Compared with women on placebo, women on oral conjugated equine estrogens were less likely to have any increase in epicardial adipose tissue (odds ratio for oral conjugated equine estrogens versus placebo: 0.62 [95% CI, 0.40–0.97]; P =0.03). PAT did not change in any group. Changes in epicardial adipose tissue and PAT did not differ by treatment group. CAC increased in 14% of participants. The assigned treatment modified the association between PAT changes and CAC progression ( P =0.02) such that PAT increases were associated with CAC increases only in the transdermal 17β‐estradiol group. Conclusions In recently menopausal women, oral conjugated equine estrogens may slow epicardial adipose tissue accumulation, whereas transdermal 17β‐estradiol may increase progression of CAC associated with PAT accumulation. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00154180.
Trajectory of Improvement in Myelopathic Symptoms From 3 to 12 Months Following Surgery for Degenerative Cervical Myelopathy
Khan, Inamullah , Archer, Kristin R. , Wanner, John Paul , Bydon, Mohamad , Pennings, Jacquelyn S. , Sivaganesan, Ahilan, Knightly, John J. , Foley, Kevin T. , Bisson, Erica F. , Shaffrey, Christopher I. , McGirt, Matthew J., Asher, Anthony L. , Devin, Clinton J. , MD, QOD Vanguard Sites Asher Anthony L MD McGirt Matthew J MD Devin Clinton J MD Foley Kevin T MD Sorenson Jeffrey M MD Briggs Thomas B MD Kremer Adam MD Griffitt Wesley E MD Bisson Erica F MD Shaffrey Mark E Shaffrey Christopher MD Fassett Daniel MD Oetting Gregory MD Elowitz Eric H MD Rumana Christopher, Sorenson, Jeffrey, Briggs, Thomas B., Kremer, Adam, Griffitt, Wesley E., Shaffrey, Mark E., Fassett, Daniel R. , Oetting, Gregory, Elowitz, Eric , Rumana, Christopher S., MD, QOD Vanguard Sites Asher Anthony L MD McGirt Matthew J MD Devin Clinton J MD Foley Kevin T MD Sorenson Jeffrey M MD Briggs Thomas B MD Kremer Adam MD Griffitt Wesley E MD Bisson Erica F MD Shaffrey Mark E Shaffrey Christopher MD Fassett Daniel MD Oetting Gregory MD Elowitz Eric H MD Rumana Christopher

Mayo Clinic

Neurosurgery | July 31, 2019 | Volume: 86 | Issue: 6 | Pages: 763-768

10.1093/neuros/nyz325 | PMID 31435676 Get It

Abstract BACKGROUND Degenerative cervical myelopathy (DCM) is a progressive disease resulting from cervical cord compression. The modified Japanese Orthopaedic Association (mJOA) is commonly used to grade myelopathic symptoms, but its persistent postoperative improvement has not been previously explored. OBJECTIVE To utilize the Quality Outcomes Database (QOD) to evaluate the trajectory of outcomes in those operatively treated for DCM. METHODS This study is a retrospective analysis of prospectively collected data. The QOD was queried for patients undergoing elective surgery for DCM. Patients were divided into mild (≥14), moderate (9-13), or severe (<9) categories for their baseline severity of myelopathic symptoms (mJOA scores). A parsimonious multivariable logistic regression model was fitted with 2 points improvement on mJOA from 3- to 12-mo follow-up as the outcome of interest. RESULTS A total of 2156 patients who underwent elective surgery for DCM and had complete 3- and 12-mo follow-up were included in our analysis. Patients improved significantly from baseline to 3-mo on their mJOA scores, regardless of their baseline mJOA severity. After adjusting for the relevant preoperative characteristics, the baseline mJOA categories had significant impact on outcome of whether a patient keeps improving in mJOA score from 3 to 12 mo postsurgery. Patient with severe mJOA score at baseline had a higher likelihood of improvement in their myelopathic symptoms, compared to patients with mild mJOA score in. CONCLUSION Most patients achieve improvement on a shorter follow-up; however, patients with severe symptoms keep on improving until after a longer follow-up. Preoperative identification of such patients helps the clinician settling realistic expectations for each follow-up timepoint.
Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial
Criner, Gerard J. , Delage, Antoine, Voelker, Kirk , Majid, Adnan , Zgoda, Michael, Lazarus, Donald R. , Casal, Roberto F. , Benzaquen, Sadia , Holladay, Robert, Wellikoff, Adam, Calero, Karel , Rumbak, Mark J., Branca, Paul, Abu‐Hijleh, Muhanned , Sachdeva, Ashutosh , Kinsey, C. Matthew , Lamb, Carla, Reed, Michael F. , Abouzgheib, Wissam , Kaplan, Phillip V., Marrujo, Gregory X., Johnstone, David W., Gasparri, Mario, Meade, Arturo A., Reddy, Chakravarthy, Case, Amy Hajari , Makani, Samir, Shepherd, Ray W., Holt, Gregory E. , Martel, Simon , Herth, Felix , Mallea, Jorge M. , Kalhan, Ravi , Criner, Gerard , Hogarth, D. Kyle , Kalhan, Ravi , Hergott, Christopher A. , Mularski, Richard A. , Chen, Benson S.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 31, 2019 | Volume: 200 | Issue: 11 | Pages: 1354-1362

10.1164/rccm.201902-0383oc | PMID 31365298 Get It

Abstract Rationale Less invasive, nonsurgical approaches are needed to treat severe emphysema. Objectives To evaluate the effectiveness and safety of the Spiration Valve System (SVS) versus optimal medical management. Methods In this multicenter, open-label, randomized, controlled trial, subjects aged 40 years or older with severe, heterogeneous emphysema were randomized 2:1 to SVS with medical management (treatment) or medical management alone (control). Measurements and Main Results The primary efficacy outcome was the difference in mean FEV1 from baseline to 6 months. Secondary effectiveness outcomes included: difference in FEV1 responder rates, target lobe volume reduction, hyperinflation, health status, dyspnea, and exercise capacity. The primary safety outcome was the incidence of composite thoracic serious adverse events. All analyses were conducted by determining the 95% Bayesian credible intervals (BCIs) for the difference between treatment and control arms. Between October 2013 and May 2017, 172 participants (53.5% male; mean age, 67.4 yr) were randomized to treatment (n = 113) or control (n = 59). Mean FEV1 showed statistically significant improvements between the treatment and control groups—between-group difference at 6 and 12 months, respectively, of 0.101 L (95% BCI, 0.060–0.141) and 0.099 L (95% BCI, 0.048–0.151). At 6 months, the treatment group had statistically significant improvements in all secondary endpoints except 6-minute-walk distance. Composite thoracic serious adverse event incidence through 6 months was greater in the treatment group (31.0% vs. 11.9%), primarily due to a 12.4% incidence of serious pneumothorax. Conclusions In patients with severe heterogeneous emphysema, the SVS shows significant improvement in multiple efficacy outcomes, with an acceptable safety profile. Clinical trial registered with www.clinicaltrials.gov (NCT01812447).
Rates of lobar atrophy in asymptomatic MAPT mutation carriers
Senjem, Matthew L. , Tosakulwong, Nirubol , Lesnick, Timothy G. , Brushaber, Danielle , Dheel, Christina, Fields, Julie A. , Forsberg, Leah K. , Gavrilova, Ralitza H. , Gearhart, Debra, Graff‐Radford, Jonathan, Graff‐Radford, Neill R., Jack, Clifford R. , Kremers, Walter K. , Rademakers, Rosa , Syrjanen, Jeremy A. , Boxer, Adam L. , Rosen, Howie, Kantarci, Kejal , Senjem, Matthew, Jack, Clifford R , Senjem, Matthew L , Kantarci, Kejal , Kremers, Walter K , Chen, Qin , Boeve, Bradley F. , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Jones, David T. , Knopman, David S. , Lapid, Maria I. , Wszołek, Zbigniew K.

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | July 30, 2019 | Volume: 5 | Issue: 1 | Pages: 338-346

10.1016/j.trci.2019.05.010 | PMID 31388560 Get It

Abstract Introduction The aim of this study was to investigate the rates of lobar atrophy in the asymptomatic microtubule‐associated protein tau ( MAPT ) mutation carriers. Methods MAPT mutation carriers (n = 14; 10 asymptomatic, 4 converters from asymptomatic to symptomatic) and noncarriers (n = 13) underwent structural magnetic resonance imaging and were followed annually with a median of 9.2 years. Longitudinal changes in lobar atrophy were analyzed using the tensor‐based morphometry with symmetric normalization algorithm. Results The rate of temporal lobe atrophy in asymptomatic MAPT mutation carriers was faster than that in noncarriers. Although the greatest rate of atrophy was observed in the temporal lobe in converters, they also had increased atrophy rates in the frontal and parietal lobes compared to noncarriers. Discussion Accelerated decline in temporal lobe volume occurs in asymptomatic MAPT mutation carriers followed by the frontal and parietal lobe in those who have become symptomatic. The findings have implications for monitoring the progression of neurodegeneration during clinical trials in asymptomatic MAPT mutation carriers.
Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma
Wang, Yucai , Link, Brian K. , Witzig, Thomas E. , Maurer, Matthew J. , Allmer, Cristine, King, Rebecca L. , Feldman, Andrew L. , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Witzig, T.E. , Feldman, Andrew L , Maurer, Matthew , Link, Brian K , Wang, Yucai , Habermann, Thomas M. , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

Blood | July 26, 2019 | Volume: 134 | Issue: 16 | Pages: 1289-1297

10.1182/blood.2019000858 | PMID 31350266 Get It

Abstract In this month's CME article, an analysis of over 1300 patients with diffuse large B-cell lymphoma (DLBCL), Wang et al demonstrate that the approximately 13% of patients with concurrent indolent lymphoma at diagnosis had the same prognosis as those patients with isolated DLBCL.
PERSISTENT PLACOID MACULOPATHY-LIKE FINDINGS IN PATIENTS WITH GIANT CELL ARTERITIS
Starr, Matthew R. , Fairbanks, Aaron M. , Geraets, Ryan D., Chen, John , Pulido, José S. , Chen, John J. , Chen, John J , Starr, Matthew R

Mayo Clinic

RETINAL Cases & Brief Reports | July 24, 2019 | Volume: 15 | Issue: 6 | Pages: 682-687

10.1097/icb.0000000000000894 | PMID 31343560 Get It

Purpose: To describe two patients with giant cell arteritis who presented with macular lesions mimicking persistent placoid maculopathy. Methods: Retrospective case reports. Patient: Two patients, a 74-year-old man and an 85-year-old woman both were diagnosed with biopsy-confirmed giant cell arteritis with vision loss in one eye due to arteritic ischemic optic neuropathy. Both presented many years later with acute vision loss in the remaining eye. Results: Both patients had bilateral retinal whitening in the parafovea, and the second also had sectoral optic disk swelling. On fluorescein angiography, these areas of retinal whitening in both patients were hypofluorescent early with late hyperfluorescence staining. On indocyanine green angiography, there were areas of foveal hypocyanescence bilaterally in both patients that persisted throughout the imaging and were more apparent late. These findings can be seen in patients with bilateral persistent placoid maculopathy. Conclusion: Giant cell arteritis should be included in the differential diagnosis of persistent placoid maculopathy.
Molecular profiling of long-term IDH-wildtype glioblastoma survivors
Yang, Jie , Decker, Paul A. , Kollmeyer, Thomas M. , Kosel, Matthew , Mladek, Ann C. , Caron, Alissa, Kitange, Gaspar J. , Sicotte, Hugues , Youland, Ryan S. , Voss, Jesse S. , Kolsky, K. L., Meyer, Fredric B. , Parney, Ian, Kipp, Benjamin R. , Sulman, Erik P. , Jenkins, Robert B. , Eckel‐Passow, Jeanette E. , Burgenske, Danielle M. , Caron, Alissa A, Gupta, Shiv K. , Fritcher, Emily G. Barr , Kolsky, Kathryn L, Parney, Ian J, Kollmeyer, Thomas , Sulman, Erik P , Mladek, Ann C , Decker, Paul A. , Vaubel, Rachael A. , Remonde, Dioval , Ida, Cristiane M. , Lachance, Daniel Honore , Giannini, Caterina , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | July 24, 2019 | Volume: 21 | Issue: 11 | Pages: 1458-1469

10.1093/neuonc/noz129 | PMID 31346613 Get It

AbstractBackgroundGlioblastoma (GBM) represents an aggressive cancer type with a median survival of only 14 months. With fewer than 5% of patients surviving 5 years, comprehensive profiling of these rare patients could elucidate prognostic biomarkers that may confer better patient outcomes. We utilized multiple molecular approaches to characterize the largest patient cohort of isocitrate dehydrogenase (IDH)–wildtype GBM long-term survivors (LTS) to date.MethodsRetrospective analysis was performed on 49 archived formalin-fixed paraffin embedded tumor specimens from patients diagnosed with GBM at the Mayo Clinic between December 1995 and September 2013. These patient samples were subdivided into 2 groups based on survival (12 LTS, 37 short-term survivors [STS]) and subsequently examined by mutation sequencing, copy number analysis, methylation profiling, and gene expression.ResultsOf the 49 patients analyzed in this study, LTS were younger at diagnosis (P = 0.016), more likely to be female (P = 0.048), and MGMT promoter methylated (UniD, P = 0.01). IDH-wildtype STS and LTS demonstrated classic GBM mutations and copy number changes. Pathway analysis of differentially expressed genes showed LTS enrichment for sphingomyelin metabolism, which has been linked to decreased GBM growth, invasion, and angiogenesis. STS were enriched for DNA repair and cell cycle control networks.ConclusionsWhile our findings largely report remarkable similarity between these LTS and more typical STS, unique attributes were observed in regard to altered gene expression and pathway enrichment. These attributes may be valuable prognostic markers and are worth further examination. Importantly, this study also underscores the limitations of existing biomarkers and classification methods in predicting patient prognosis.